record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
Carvalho et al. 2019 Communications Biology
authors
reviewer:will-blair
ALK2 inhibitors (LDN212854, LDN214117, LDN193189) cross the blood-brain barrier, suppress ACVR1-mutant DIPG growth in orthotopic xenografts, and significantly extend survival in preclinical models.
vs_150c1fec7f38f4a5 · manual_curation
outgoing
vf_97bb0892807d6ac9ALK2 monotherapy extends survival in ACVR1-mutant xenografts; GD2-CAR T achieves clinical response in unselected H3K27M DIPG, indicating ACVR1-wt cases may require multi-modal or immunotherapy approach
events
vev_03ce881199035ec4finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_b39b714fb06f8a3efinding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.